Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER INC : JP Morgan reiterates its Neutral rating

11/29/2021 | 04:51pm EST

Analyst Chris Schott from JP Morgan research gives the stock a Neutral rating. The target price has been revised upwards and is now set at USD 53, compared with USD 42 previously.


ę MarketScreener with dpa-AFX Analyser 2021
All news about PFIZER, INC.
01:22pCanada approves Pfizer COVID drug
AQ
12:53pCanada approves Pfizer COVID drug as hospitalizations rise and kids return to school
AQ
12:50pHealth Canada approves Pfizer antiviral but supply issues expected
AQ
11:23aCanadian Regulator Approves Use of Pfizer Oral Drug for Covid-19
DJ
11:04aGLOBAL MARKETS LIVE : Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...
10:37aCanada approves Pfizer's oral COVID-19 antiviral treatment, seeks supplies
RE
10:21aHealth Canada To OK Pfizer's COVID-19 Antiviral Pill
MT
10:10aCanada has approved Pfizer's COVID-19 oral antiviral treatment - government website
RE
09:18aPfizer Inc - U.S. FDA Approves Pfizer's CIBINQO (abrocitinib) for Adults with Moderate-..
AQ
08:08aMARKETSCREENER’S WORLD PRESS REVIEW : January 17, 2022
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 916 M - -
Net income 2021 22 210 M - -
Net Debt 2021 27 661 M - -
P/E ratio 2021 14,4x
Yield 2021 2,88%
Capitalization 308 B 308 B -
EV / Sales 2021 4,10x
EV / Sales 2022 3,31x
Nbr of Employees 78 500
Free-Float -
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 54,95 $
Average target price 57,10 $
Spread / Average Target 3,90%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-6.94%308 427
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444